Novel Neoadjuvant Approach May Boost Surgical Success in Pancreatic Cancer Novel Neoadjuvant Approach May Boost Surgical Success in Pancreatic Cancer

In the majority of studied patients with locally advanced pancreatic cancer, total neoadjuvant treatment with fluorouracil, leucovorin, oxaliplatin and irinotecan (FOLFIRINOX) along with losartan and chemoradiation allowed complete tumor removal, according to a single-arm phase 2 trial.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Related Links:

Authors: Choi YH, Lee SH, You MS, Shin BS, Paik WH, Ryu JK, Kim YT, Kwon W, Jang JY, Kim SW Abstract Background/Aims: There has been growing evidence on the utility of neoadjuvant FOLFIRINOX in borderline resectable (BR) or locally advanced (LA) pancreatic cancer. However, factors predicting survival in these patients remain to be identified, and we aimed to identify these prognostic factors. Methods: Between January 2013 and April 2017, patients with BR or LA pancreatic cancer who received FOLFIRINOX as their initial treatment were identified. Demographic data and clinical outcomes, including the chemotherapy ...
Source: Gut and Liver - Category: Gastroenterology Tags: Gut Liver Source Type: research
The incidence of pancreatic ductal adenocarcinoma has risen rapidly. By 2030, it is likely to be the second most prevalent cause of death by cancer, following cancer of the lung. Unfortunately, most patients present with advanced disease. In fact, only 20% of patients are candidates for surgery. More research is needed to find dependable treatment options for this disease. Although we wait for more effective treatments to be developed, we continue using chemotherapy, radiation, and surgery—all with less than optimal outcomes. There is a debate about using chemotherapy in the neoadjuvant setting and counter-debate abo...
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Review Article Source Type: research
Conclusions In early-stage PC, QLQ-C30 and QLQ-PAN26 are the most commonly used PROMs. Baseline QLQ-C30 global health status/QoL scores suggested a high humanistic burden. Immediately after surgery, QoL declined but seemed stable over the longer term. The QLQ-C30 MID may elucidate the clinical impact of treatment on QoL; MID for QLQ-PAN26 needs to be established.
Source: Pancreas - Category: Gastroenterology Tags: Original Articles Source Type: research
No abstract available
Source: Pancreas - Category: Gastroenterology Tags: Letters to the Editor Source Type: research
Thanks to the development of modern chemotherapeutic regimens, survival after surgery for pancreatic ductal adenocarcinoma (PDAC) has improved and pancreatologists worldwide agree that the treatment of PDAC demands a multidisciplinary approach. Neoadjuvant treatment (NAT) plays a major role in the treatment of PDAC since only about 20% of patients are considered resectable at the time of diagnosis. Moreover, increasing data demonstrating the benefits of NAT for borderline resectable/locally advanced PDAC are driving a shift from up-front surgery to NAT in the multidisciplinary treatment of even resectable PDAC. Our underst...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Pancreatic cancer is the fourth leading cause of cancer mortality in the United States [1]. In patients with localized disease, surgical resection remains central to curative-intent treatment, but surgery alone is associated with high rates of recurrence [2,3]. Increasingly, a neoadjuvant approach to pancreatic cancer treatment is gaining interest [2,4]. Its advantages include treatment of better perfused/better oxygenated tumor, preoperative shrinkage of tumor with potential for increased margin-negative resection rate, increased chemotherapy delivery, and earlier treatment of micrometastatic disease [3].
Source: Radiotherapy and Oncology - Category: Radiology Authors: Source Type: research
CONCLUSIONS: Neoadjuvant chemotherapy with SBRT is associated with favorable survival and pathological outcomes, warranting consideration for prospective validation. PMID: 32044168 [PubMed - as supplied by publisher]
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - Category: Radiology Authors: Tags: Radiother Oncol Source Type: research
Approximately 20% of pancreatic ductal adenocarcinoma (PDAC) patients have (borderline) resectable pancreatic cancer [(B)RPC] at diagnosis. Upfront resection with adjuvant chemotherapy has long been the standard of care for these patients. However, although surgical quality has improved, still about 50% of patients never receive adjuvant treatment. Therefore, recent developments have focused on a neoadjuvant approach. Directly comparing results from neoadjuvant and adjuvant regimens is challenging due to differences in patient populations that influence outcomes. Neoadjuvant trials include all patients who have (B)RPC on i...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
AbstractThe prognosis of patients with pancreatic cancer continues to remain dismal, even though numerous trials have been conducted to establish more effective therapies in Japan and throughout the world. Recent advances in treatment have been characterized by the use of novel combinations of conventional cytotoxic chemotherapies. Especially in Japan, S-1 has become one of the most widely used cytotoxic agents for the treatment of pancreatic cancer, after clinical evidence was established of the survival benefit offered by this drug for patients with resectable or unresectable pancreatic cancer. Unfortunately, with the ex...
Source: Journal of Gastroenterology - Category: Gastroenterology Source Type: research
Abstract Pancreatic ductal adenocarcinoma is an aggressive cancer with high recurrence rates following surgical resection. While adjuvant chemotherapy improves survival, a significant proportion of patients are unable to initiate or complete all intended therapy following pancreatectomy due to postoperative complications or poor performance status. The administration of chemotherapy prior to surgical resection is an alternative strategy that ensures its early and near universal delivery as well as improves margin-negative resection rates and potentially improves long-term survival outcomes. Neoadjuvant therapy is ...
Source: World Journal of Gastroenterology : WJG - Category: Gastroenterology Authors: Tags: World J Gastroenterol Source Type: research
More News: Cancer | Cancer & Oncology | Cozaar | Eloxatin | Health | Hematology | Losartan | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Pancreas | Pancreatic Cancer